Covid-19 roundup: GSK CEO Emma Walmsley — some trial delays, but we’re limiting the damage — so far; Trump planning ‘Warp Speed’ vaccine plan
All the major pharmas are wrestling with the Covid-19 outbreak in one way or another. For some, like Eli Lilly, the executive teams have delayed patient recruitment on a wide number of trials, which will likely have a deep impact on development plans — particularly at the earlier stages.
But over at GlaxoSmithKline, the emphasis has been on finding ways to keep its operations on track — including R&D. Here’s a lengthy set of remarks from Emma Walmsley’s Q1 review, which help encapsulate both the effects of the outbreak and their strategy for dealing with it.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.